ZD 9255

Drug Profile

ZD 9255

Latest Information Update: 07 Apr 1999

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Anti-ischaemics; Neuroprotectants; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Purinergic P1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cerebrovascular disorders; Intermittent claudication; Ischaemic heart disorders; Peripheral vascular disorders

Most Recent Events

  • 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed
  • 18 Jan 1996 Discontinued-Preclinical for Cerebrovascular disorders in United Kingdom (Unknown route)
  • 18 Jan 1996 Discontinued-Preclinical for Peripheral vascular disorders in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top